Status:
TERMINATED
Secondary Prevention of Atrial Fibrilation
Lead Sponsor:
Boston Medical Center
Collaborating Sponsors:
Boston University
Conditions:
Atrial Fibrillation
Risk Factors
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Atrial fibrillation (AF) is the most common arrhythmia affecting over 3 million Americans and about 33.5 million individuals globally. The lifetime risk of developing AF is 1 in 4 for adults over age ...
Detailed Description
The proposed study is designed as a Hybrid Type 3 effectiveness-implementation study. This study design will enable the investigators to primarily focus on core implementation outcomes while also asse...
Eligibility Criteria
Inclusion
- Age 18 years or older
- Diagnosis of paroxysmal AF (based on 12-lead electrocardiogram or event monitor showing AF).
- Body mass index of greater than 27 kg/m2
- Eligibility to participate in cardiac rehabilitation with negative exercise stress test within 6 months.
Exclusion
- Permanent AF.
- Undergone catheter ablation of AF in past 6 months.
- Class I or Class III anti-arrhythmic drugs at the time of enrollment
- Unable to participate in cardiac rehabilitation.
- Prognosis of less than 1-year.
- Do not own a smart phone.
- Unable to operate (transmit data) their smart phone.
- Are not fluent in English or Spanish.
- Unable to read in English or Spanish.
- Not able to provide informed consent.
- Women who are pregnant.
- Prisoners.
Key Trial Info
Start Date :
February 1 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 11 2020
Estimated Enrollment :
3 Patients enrolled
Trial Details
Trial ID
NCT03259893
Start Date
February 1 2018
End Date
May 11 2020
Last Update
January 26 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Boston Medical Center
Boston, Massachusetts, United States, 02118